206 related articles for article (PubMed ID: 19192278)
1. Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma.
Lavarino C; Cheung NK; Garcia I; Domenech G; de Torres C; Alaminos M; Rios J; Gerald WL; Kushner B; LaQuaglia M; Mora J
BMC Cancer; 2009 Feb; 9():44. PubMed ID: 19192278
[TBL] [Abstract][Full Text] [Related]
2. MYCN gain and MYCN amplification in a stage 4S neuroblastoma.
Noguera R; Cañete A; Pellín A; Ruiz A; Tasso M; Navarro S; Castel V; Llombart-Bosch A
Cancer Genet Cytogenet; 2003 Jan; 140(2):157-61. PubMed ID: 12645655
[TBL] [Abstract][Full Text] [Related]
3. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
4. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Clin Cancer Res; 2003 Jan; 9(1):52-8. PubMed ID: 12538451
[TBL] [Abstract][Full Text] [Related]
5. MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S.
Bénard J; Raguénez G; Kauffmann A; Valent A; Ripoche H; Joulin V; Job B; Danglot G; Cantais S; Robert T; Terrier-Lacombe MJ; Chassevent A; Koscielny S; Fischer M; Berthold F; Lipinski M; Tursz T; Dessen P; Lazar V; Valteau-Couanet D
Mol Oncol; 2008 Oct; 2(3):261-71. PubMed ID: 19383347
[TBL] [Abstract][Full Text] [Related]
6. Neuroblastoma: a multiple biological disease.
Tonini GP
Eur J Cancer; 1993; 29A(6):802-4. PubMed ID: 8484968
[TBL] [Abstract][Full Text] [Related]
7. Regression and progression in neuroblastoma. Does genetics predict tumour behaviour?
Ambros PF; Ambros IM; Strehl S; Bauer S; Luegmayr A; Kovar H; Ladenstein R; Fink FM; Horcher E; Printz G
Eur J Cancer; 1995; 31A(4):510-5. PubMed ID: 7576955
[TBL] [Abstract][Full Text] [Related]
8. Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p.
Mora J; Cheung NK; Kushner BH; LaQuaglia MP; Kramer K; Fazzari M; Heller G; Chen L; Gerald WL
J Mol Diagn; 2000 Feb; 2(1):37-46. PubMed ID: 11272900
[TBL] [Abstract][Full Text] [Related]
9. Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531.
Twist CJ; Naranjo A; Schmidt ML; Tenney SC; Cohn SL; Meany HJ; Mattei P; Adkins ES; Shimada H; London WB; Park JR; Matthay KK; Maris JM
J Clin Oncol; 2019 Jan; 37(2):115-124. PubMed ID: 30444686
[TBL] [Abstract][Full Text] [Related]
10. Low DLG2 gene expression, a link between 11q-deleted and MYCN-amplified neuroblastoma, causes forced cell cycle progression, and predicts poor patient survival.
Keane S; Améen S; Lindlöf A; Ejeskär K
Cell Commun Signal; 2020 Apr; 18(1):65. PubMed ID: 32312269
[TBL] [Abstract][Full Text] [Related]
11. Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2(SSTR2) gene at 17q24.
Abel F; Ejeskär K; Kogner P; Martinsson T
Br J Cancer; 1999 Dec; 81(8):1402-9. PubMed ID: 10604740
[TBL] [Abstract][Full Text] [Related]
12. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).
Schleiermacher G; Michon J; Ribeiro A; Pierron G; Mosseri V; Rubie H; Munzer C; Bénard J; Auger N; Combaret V; Janoueix-Lerosey I; Pearson A; Tweddle DA; Bown N; Gerrard M; Wheeler K; Noguera R; Villamon E; Cañete A; Castel V; Marques B; de Lacerda A; Tonini GP; Mazzocco K; Defferrari R; de Bernardi B; di Cataldo A; van Roy N; Brichard B; Ladenstein R; Ambros I; Ambros P; Beiske K; Delattre O; Couturier J
Br J Cancer; 2011 Dec; 105(12):1940-8. PubMed ID: 22146831
[TBL] [Abstract][Full Text] [Related]
13. Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4s neuroblastomas.
Brinkschmidt C; Poremba C; Christiansen H; Simon R; Schäfer KL; Terpe HJ; Lampert F; Boecker W; Dockhorn-Dworniczak B
Br J Cancer; 1998 Jun; 77(12):2223-9. PubMed ID: 9649137
[TBL] [Abstract][Full Text] [Related]
14. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.
Spitz R; Hero B; Skowron M; Ernestus K; Berthold F
Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958
[TBL] [Abstract][Full Text] [Related]
15. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
16. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome.
Brinkschmidt C; Christiansen H; Terpe HJ; Simon R; Lampert F; Boecker W; Dockhorn-Dworniczak B
Med Pediatr Oncol; 2001 Jan; 36(1):11-3. PubMed ID: 11464859
[TBL] [Abstract][Full Text] [Related]
17. Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease.
Mora J; Cheung NK; Chen L; Qin J; Gerald W
Cancer; 2001 Jan; 91(2):435-42. PubMed ID: 11180092
[TBL] [Abstract][Full Text] [Related]
18. Age-dependent accumulation of genomic aberrations and deregulation of cell cycle and telomerase genes in metastatic neuroblastoma.
Coco S; Theissen J; Scaruffi P; Stigliani S; Moretti S; Oberthuer A; Valdora F; Fischer M; Gallo F; Hero B; Bonassi S; Berthold F; Tonini GP
Int J Cancer; 2012 Oct; 131(7):1591-600. PubMed ID: 22234802
[TBL] [Abstract][Full Text] [Related]
19. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status.
Simon T; Spitz R; Faldum A; Hero B; Berthold F
J Pediatr Hematol Oncol; 2004 Dec; 26(12):791-6. PubMed ID: 15591897
[TBL] [Abstract][Full Text] [Related]
20. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene.
Carén H; Erichsen J; Olsson L; Enerbäck C; Sjöberg RM; Abrahamsson J; Kogner P; Martinsson T
BMC Genomics; 2008 Jul; 9():353. PubMed ID: 18664255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
